Actively Recruiting
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Led by Institut Curie · Updated on 2026-04-17
300
Participants Needed
21
Research Sites
330 weeks
Total Duration
On this page
Sponsors
I
Institut Curie
Lead Sponsor
Z
Zionexa
Collaborating Sponsor
AI-Summary
What this Trial Is About
Eclectic is a strategy trial; once the class of treatment (endocrine therapy or chemotherapy) has been allocated according to 16α-18F-fluoro-17β-oestradiol (18F-FES) Positron Emission Tomography/Computed Tomography (PET/CT) results and circulating tumor biomarkers, clinicians will decide which treatment to use.
CONDITIONS
Official Title
ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Metastatic invasive breast carcinoma of no special type
- Female or male aged 18 years or older
- Life expectancy longer than 3 months
- ECOG performance status 0 to 2
- ER-positive (at least 10%) and HER2-negative breast cancer per local assessment
- Available tumor tissue block (primary tumor or metastasis)
- Disease progressed on first line endocrine therapy with aromatase inhibitor and CDK4/6 inhibitor after more than 6 months
- Available 18F-FDG PET/CT imaging
- Evaluable disease per RECIST and measurable disease per PERCIST criteria
- Willing and able to follow scheduled visits, treatment plan, and protocol procedures
- Signed informed consent
- Affiliated with a social security system
You will not qualify if you...
- Breast cancer subtype other than no special type (e.g., invasive lobular breast carcinoma)
- Any prior chemotherapy lines in metastatic setting
- Any systemic treatment other than first line endocrine therapy with aromatase inhibitor and CDK4/6 inhibitor for metastatic disease
- Visceral crisis as assessed by investigator
- Liver-only metastases
- Prior use of agents degrading the estrogen receptor (fulvestrant, oral SERDs, PROTAC, etc.)
- Pregnancy or breastfeeding
- Women of childbearing potential or premenopausal women without adequate non-hormonal contraception
- Positive pregnancy test within 72 hours before 18F-FES PET/CT
- Active uncontrolled or symptomatic central nervous system metastases or related conditions, unless treated and stable for at least 4 weeks
- History of other cancers or blood cancers within 3 years before enrollment, except multiple primary ER+ HER2- breast tumors
- Persons deprived of liberty, under guardianship, or unable to consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 21 locations
1
Centre Hospitalier de la Côte basque
Bayonne, France, 64100
Not Yet Recruiting
2
Institut Bergonié
Bordeaux, France, 33076
Not Yet Recruiting
3
Polyclinique Bordeaux Nord Aquitaine
Bordeaux, France, 33077
Not Yet Recruiting
4
Centre Francois Baclesse
Caen, France, 14076
Actively Recruiting
5
Centre Georges Francois Leclerc
Dijon, France, 21079
Actively Recruiting
6
Centre Oscar Lambret
Lille, France, 59000
Actively Recruiting
7
CHU Limoges
Limoges, France, 87000
Not Yet Recruiting
8
Centre Leon Bérard
Lyon, France, 69008
Not Yet Recruiting
9
Institut Paoli-Calmettes
Marseille, France, 13009
Actively Recruiting
10
Institut du Cancer Montpellier
Montpellier, France, 34298
Actively Recruiting
11
Centre Antoine lacassagne
Nice, France, 06189
Actively Recruiting
12
Hôpital Universitaire de Nimes
Nîmes, France, 30029
Not Yet Recruiting
13
Institut Curie
Paris, France, 75005
Actively Recruiting
14
Centre Eugène Marquis
Rennes, France, 35042
Actively Recruiting
15
Centre Henri Becquerel
Rouen, France, 76038
Not Yet Recruiting
16
Institut Curie
Saint-Cloud, France, 92210
Actively Recruiting
17
Bruno MAUCHERAT
Saint-Herblain, France, 44805
Withdrawn
18
Centre de lutte contre le cancer Paul Strauss
Strasbourg, France
Not Yet Recruiting
19
Oncopole Claudius Regaud
Toulouse, France, 31059
Not Yet Recruiting
20
Hôpital Bretonneau-CHU Tours
Tours, France, 37044
Not Yet Recruiting
21
Institut de Cancerologie de Lorraine
Vandœuvre-lès-Nancy, France, 54519
Actively Recruiting
Research Team
F
François-Clément BIDARD, PhD
CONTACT
I
Isabelle TURBIEZ
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here